Data capture is no longer the bottleneck, and whether the lag between a signal and a decision shrinks depends on signal design, AI governance, and vendor orchestration.
|Webcasts|October 26, 2021
2021 Research: The Impact of New Clinical Trial Approaches Adopted During Pandemic
Author(s)Oracle Health Sciences
***Live: Tuesday, October 26, 2021 at 11 EDT | 8am PDT | 5pm CEST | 4pm BST*** Oracle Health Sciences reveals new research conducted to understand the technology adaptations that were made to clinical trials during the pandemic, the effect of these adaptations, and the impact of these changes on the future of clinical trials.
Register free:
Event Overview:
The COVID-19 pandemic radically changed the world in an instant and forced adaption across the board. In the Life Sciences industry, those conducting clinical trials had to quickly adjust to support new ways of monitoring and caring for clinical trial participants in a world where physical access was not an option.
As we look toward a post-pandemic world, Oracle , in partnership with Informa Pharma Intelligence conducted a global, industry-wide survey to understand the adaptations that were made to clinical trials during the pandemic, the effect of these adaptations, and the impact of these changes on the future of clinical trials.
The research forecasts the continuation, as well as discontinuation, of certain approaches such as EHR, eSource, ePro, and patient apps – and the impact of these approaches on clinical trial data, quality , and speed. It will also shed light on the industry’s level of confidence in the data generated from these new clinical trial approaches, in comparison to data collected via pre-pandemic methods, and other expectations as we step forward into the post-pandemic world.
Key Learning Objectives:
Join this webinar to also understand if your peers:
- View the impact of the changes made during the pandemic as positive or negative
- Plan to increase or decrease their use of DCT, hybrid, and fit-for-purpose clinical trial models
- Plan to give patients the option to choose how they participate in clinical trial
Who Should Attend:
- Director, VP level, and Executive Management
- Clinical Operations and Innovations
- Professionals seeking further knowledge on how to develop their digital strategy for clinical trials
Speakers:
Kristin Letourneau
PhD - Director of Market Research
Informa Engage
Jim Streeter
Global Vice President Life Science Customer Success
Oracle Health Sciences
Time and Date: Tuesday, October 26, 2021 at 11 EDT | 8am PDT | 5pm CEST | 4pm BST
On demand available after final airing until Oct. 26, 2022
Sponsor: Oracle Health Sciences
Register free:
Related to this article
In this Q&A, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, discusses what changes when AI is embedded across protocol strategy, data infrastructure, and workflow tools at once, where governance frameworks tend to fall short, and why CROs must orchestrate AI ecosystems rather than simply aggregate them.
In today’s ACT Brief, we examine what policy changes would help community and rural institutions join research, how Walmart is expanding clinical trial centers into three more states, and how FDA approved Ilumya for adults with active psoriatic arthritis.
The planned sites in Livonia, Las Vegas, and San Antonio would expand a partnership that places clinical research and health screenings inside Walmart stores.
In this video interview, Kent Thoelke, CEO of Paradigm Health, calls for safe harbor protections, CMS reimbursement safeguards, and funding mechanisms modeled on EHR meaningful use to help community and rural institutions participate in research on par with academic centers.
In today’s ACT Brief, we examine why community and rural patients lack access to research as a care option, what makes AI assistants trustworthy in regulated trials, and how FDA draft guidance could let gene editing therapies cover patient-specific variants.
In this Q&A, E.K. Koh, chief product officer at Suvoda, discusses what separates a trustworthy AI assistant from one that adds risk, why curated clinical knowledge matters more than general-purpose flexibility, and what safeguards must be in place when assistants move from answering questions to taking actions in clinical trial systems.
In this video interview, Kent Thoelke, CEO of Paradigm Health, explains why patients in community and rural settings too often lack access to clinical research as a care option, and how closing that gap could improve outcomes and lower long-term costs.
Trending on Applied Clinical Trials Online
1
Building AI Assistants Clinical Trial Teams Can Trust: Q&A with E.K. Koh, Suvoda
2
What Needs to Happen Beyond the Clinical Trial Modernization Act
3
From Signal to Action: Why Faster Trial Data Isn’t Producing Faster Decisions
4
Walmart and Care Access Plan Three More Clinical Trial Centers in Michigan, Nevada, and Texas
5